NanoViricides (NNVC)
Develops host-mimetic antiviral candidates for multiple viral diseases.
Something off on this page? Send us feedback.
Develops host-mimetic polymeric antiviral candidates and manufactures limited clinical supplies while outsourcing much of its research and clinical work. Its lead active ingredient is being developed across several viral indications, with no approved drug or product revenue.
Develops host-mimetic polymeric antiviral candidates designed to bind viruses before cell entry and disrupt them. Its lead active ingredient, NV-387, is being advanced across MPox, measles, smallpox, respiratory infections, and other viral targets; a topical NV-HHV-1 skin cream remains deferred.
Research, analytical work, and limited clinical-supply manufacture are centered in Shelton, Connecticut, while clinical and development work relies on TheraCour, contract research organizations, laboratories, and partners in India and the DRC. The company owns an approximately 18,000-square-foot facility but has no large-scale commercial manufacturing, sales, or marketing organization.
Has no approved drug, customer, or product revenue. Core technology rights, development, and supply are licensed from and dependent on TheraCour, which is also controlled by the founder.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $3.2M · Total debt $0 · Total assets $10.2M · Shareholders' equity $9.2M
- Revenue
- $0
- Operating income
- −$2.0M
- Net income
- −$2.0M
No dividends on record.
| Institutions49 holders · as of Mar 31, 2026 | 8.78% | 1.90M shares | |
| Otherremainder | 91.22% | 19.75M shares |
21.65M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (21.65M in the company's Sep 3, 2026 report, 25.40M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 2.36% | 511,477 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 1.04% | 225,381 | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.99% | 213,359 | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 0.73% | 158,752 | 13Fas of Mar 31, 2026 |
Renaissance Technologies LLCInstitution | 0.62% | 134,900 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- SIGA
Established orthopox antiviral and biodefense-stockpile rival.
- Emergent BioSolutions
Animal Rule smallpox treatment with stockpile relevance.
- BioCryst Pharmaceuticals
Peramivir treatment overlaps the influenza arm of respiratory use.
- Pfizer
COVID treatment and RSV prevention constrain respiratory entry.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NanoViricides | $1.17 | −0.85% | $29.7M | — | — | — | — |
| SIGA | $3.19 | −0.78% | $230.2M | — | — | 4.3 | −49.5% |
| Emergent BioSolutions | $6.42 | −0.70% | $333.3M | — | — | 0.4 | +66.3% |
| BioCryst Pharmaceuticals | $10.17 | −0.10% | $2.58B | — | 19.4 | 2.7 | +33.6% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Median | 38.3 | 14.9 | 2.7 | +18.1% |